File Download

There are no files associated with this item.

  Links for fulltext
     (May Require Subscription)
Supplementary

Article: Lyso-thermosensitive liposomal doxorubicin: A novel approach to enhance efficacy of thermal ablation of liver cancer

TitleLyso-thermosensitive liposomal doxorubicin: A novel approach to enhance efficacy of thermal ablation of liver cancer
Authors
KeywordsHepatocellular carcinoma
Lyso-thermosensitive liposomal doxorubicin
Radiofrequency ablation
Issue Date2009
PublisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eop
Citation
Expert Opinion On Pharmacotherapy, 2009, v. 10 n. 2, p. 333-343 How to Cite?
AbstractBackground: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No more than 30% of HCC patients receive curative treatment. Factors limiting curative therapy include tumor size and degree of liver impairment. Objective: To develop a cure for medium (3.1 - 5.0 cm) and large (> 5 cm) tumors in seriously impaired livers. Method: Combine radiofrequency ablation (RFA) with lyso-thermosensitive liposomal doxorubicin (LTLD). Results/conclusions: RFA is used safely in patients with medium/large tumors and severe liver impairment; unclear tumor margins limit its curative efficacy. LTLD concentrates in the liver, where the anti-HCC chemotherapeutic, doxorubicin, is released into tumor margins by hyperthermia. RFA/LTLD can treat Child-Pugh class A-B patients with tumors up to 7 cm, a substantial increase in curable patients. © 2009 Informa UK Ltd. All rights reserved.
Persistent Identifierhttp://hdl.handle.net/10722/59908
ISSN
2015 Impact Factor: 3.543
2015 SCImago Journal Rankings: 0.884
ISI Accession Number ID
References

 

DC FieldValueLanguage
dc.contributor.authorPoon, RTPen_HK
dc.contributor.authorBorys, Nen_HK
dc.date.accessioned2010-05-31T03:59:53Z-
dc.date.available2010-05-31T03:59:53Z-
dc.date.issued2009en_HK
dc.identifier.citationExpert Opinion On Pharmacotherapy, 2009, v. 10 n. 2, p. 333-343en_HK
dc.identifier.issn1465-6566en_HK
dc.identifier.urihttp://hdl.handle.net/10722/59908-
dc.description.abstractBackground: Hepatocellular carcinoma (HCC) is the fourth leading cause of cancer death worldwide. No more than 30% of HCC patients receive curative treatment. Factors limiting curative therapy include tumor size and degree of liver impairment. Objective: To develop a cure for medium (3.1 - 5.0 cm) and large (> 5 cm) tumors in seriously impaired livers. Method: Combine radiofrequency ablation (RFA) with lyso-thermosensitive liposomal doxorubicin (LTLD). Results/conclusions: RFA is used safely in patients with medium/large tumors and severe liver impairment; unclear tumor margins limit its curative efficacy. LTLD concentrates in the liver, where the anti-HCC chemotherapeutic, doxorubicin, is released into tumor margins by hyperthermia. RFA/LTLD can treat Child-Pugh class A-B patients with tumors up to 7 cm, a substantial increase in curable patients. © 2009 Informa UK Ltd. All rights reserved.en_HK
dc.languageengen_HK
dc.publisherInforma Healthcare. The Journal's web site is located at http://www.expertopin.com/loi/eopen_HK
dc.relation.ispartofExpert Opinion on Pharmacotherapyen_HK
dc.rightsExpert Opinion on Pharmacotherapy. Copyright © Informa Healthcare.en_HK
dc.subjectHepatocellular carcinomaen_HK
dc.subjectLyso-thermosensitive liposomal doxorubicinen_HK
dc.subjectRadiofrequency ablationen_HK
dc.subject.meshAntibiotics, Antineoplastic - administration and dosage - pharmacology - therapeutic use-
dc.subject.meshCarcinoma, Hepatocellular - pathology - therapy-
dc.subject.meshCatheter Ablation - methods-
dc.subject.meshDoxorubicin - administration and dosage - pharmacology - therapeutic use-
dc.subject.meshHyperthermia, Induced-
dc.titleLyso-thermosensitive liposomal doxorubicin: A novel approach to enhance efficacy of thermal ablation of liver canceren_HK
dc.typeArticleen_HK
dc.identifier.openurlhttp://library.hku.hk:4550/resserv?sid=HKU:IR&issn=1465-6566&volume=10&issue=2&spage=333&epage=343&date=2009&atitle=Lyso-thermosensitive+liposomal+doxorubicin:+a+novel+approach+to+enhance+efficacy+of+thermal+ablation+of+liver+canceren_HK
dc.identifier.emailPoon, RTP: poontp@hkucc.hku.hken_HK
dc.identifier.authorityPoon, RTP=rp00446en_HK
dc.description.naturelink_to_subscribed_fulltext-
dc.identifier.doi10.1517/14656560802677874en_HK
dc.identifier.pmid19236203-
dc.identifier.scopuseid_2-s2.0-65649146495en_HK
dc.identifier.hkuros167044en_HK
dc.relation.referenceshttp://www.scopus.com/mlt/select.url?eid=2-s2.0-65649146495&selection=ref&src=s&origin=recordpageen_HK
dc.identifier.volume10en_HK
dc.identifier.issue2en_HK
dc.identifier.spage333en_HK
dc.identifier.epage343en_HK
dc.identifier.isiWOS:000263339700014-
dc.publisher.placeUnited Kingdomen_HK
dc.identifier.scopusauthoridPoon, RTP=7103097223en_HK
dc.identifier.scopusauthoridBorys, N=26537167700en_HK
dc.identifier.citeulike3953874-

Export via OAI-PMH Interface in XML Formats


OR


Export to Other Non-XML Formats